canada clinical guidance

Acne vulgaris

A Canadian clinical summary of acne vulgaris, with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Management of acne: Canadian clinical practice guideline. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:Canadian acne guideline

Source-attributed clinical priorities

  • Grade inflammatory and comedonal acne, scarring, pigment change and psychosocial impact and review acne-promoting medicines or products.
  • Use topical combination treatment for most mild or moderate disease and add systemic therapy only for an appropriate phenotype and duration.
  • Prevent pregnancy exposure to teratogenic retinoids and refer nodulocystic, scarring, refractory or severely distressing acne.
  • Document scarring and psychological distress because either may justify earlier systemic or specialist care.
sources for this section:Canadian acne guideline

Practical assessment and management workflow

1
Grade comedones, inflammatory lesions, nodules, distribution, pigment change and scarring.
2
Review pregnancy possibility, skin products, friction and acne-promoting medicines.
3
Select complementary topical agents and explain application, irritation reduction and the time needed for response.
4
Review after an adequate trial and add oral or specialist treatment only when severity and risk warrant it.
sources for this section:Canadian acne guideline

Safety, red flags and urgent escalation

  • Prevent pregnancy exposure to oral and topical retinoids according to Canadian product requirements.
  • Severe nodulocystic or fulminant acne needs prompt dermatology assessment.
  • Avoid prolonged antibiotic monotherapy; combine and limit use to reduce resistance.
sources for this section:Canadian acne guideline

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:Canadian acne guideline

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Canadian acne guideline

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Canadian Acne Clinical Practice Guideline PanelManagement of acne: Canadian clinical practice guidelineaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.